jRCT2080222136未知3 期
Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab Plus Etoposide/Platinum Versus Etoposide/Platinum in Subjects With Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)
试验速览
- 阶段
- 3 期
- 入组人数
- 1,100
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Randomized, Double Blind, Placebo Control, Parallel Assignment Study
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)
- •Eastern Cooperative Oncology Group (ECOG) of 0 or 1
排除标准
- •Prior systemic therapy for lung cancer
- •Symptomatic Central Nervous System (CNS) metastases
- •History of autoimmune disease
结局指标
主要结局
-
Overall Survival (OS) of subjects who received blinded study therapy
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
3 期
Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancerimited Stage Small Cell Lung Cancer (LS-SCLC)D055752JPRN-jRCT2031210107Kagamu Hiroshi45
已完成
不适用
Yorkshire Collaborative Small Cell Lung Cancer Studyung (small cell)Small cell lungCancerISRCTN15654915orthern and Yorkshire Clinical Trials and Research Unit (UK)
进行中（未招募）
不适用
A PHASE II TRIAL ON NON-SMALL-CELL LUNG CANCER STEM CELLS SENSITIVITY ASSAY (LUCAS)Histologically/cytologically confirmed diagnosis of metastatic NSCLC.Possibility to obtain tumor tissue form primary tumor or from an accessible metastatic site, or possibility to collect any neoplastic effusion.Performance status of 0-1 according to ECOG score.EUCTR2012-001440-22-IT
已完成
不适用
tritional Assessment in Non-small Cell lung cancer patientslungcancerNon Small Cell Lung Cancer10038666NL-OMON50451Antoni van Leeuwenhoek Ziekenhuis100
已完成
2 期
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-EtoposideSCLC, Extensive StageNCT04221529AIO-Studien-gGmbH70